Dark

Check out our Dark Pool Levels

CMPX
Compass Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Aug 4, 2026 3:59:57 PM EDT

1.99USD+5.026%(+0.10)3,046,904

1.65Bid 1.99Ask 0.34Spread

Pre-market

Aug 4, 2026 9:28:30 AM EDT

1.89USD0.000%(0.00)4,181

After-hours

Aug 4, 2026 4:00:30 PM EDT

1.98USD-0.252%(-0.01)381,660

OverviewOptionsHistoricalExchangesShortsNews

Jan 20, 2022

08:39AM EST Compass Therapeutics Announces US FDA Clearance Of Investigational New Drug Application For A Phase 2 Study Of CTX-009, A Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 And Vascular Endothelial Growth Factor A Benzinga

08:30AM EST Compass Therapeutics Announces US FDA Clearance of Investigational GlobeNewswire Inc

Jan 19, 2022

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 Benzinga

05:17AM EST B. Riley Securities Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $10 Benzinga

Dec 22, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 Benzinga

07:13AM EST Raymond James Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $5 Benzinga

Dec 20, 2021

11:58AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021 Benzinga

06:20AM EST SVB Leerink Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $12 Benzinga

Dec 15, 2021

04:21PM EST 16:21 Wednesday, December 15, 2021Wedbush (RTTNews) - Wedbush Initiates Compass Therapeutics, Inc (CMPX) At Outperform With $8 Price Target RTTNews

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

07:09AM EST Wedbush Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $8 Benzinga

Nov 19, 2021

10:55AM EST Roth Capital Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $15 Benzinga

Nov 12, 2021

08:39AM EST Compass Therapeutics Q3 2021 EPS $(0.10) Benzinga

Nov 9, 2021

11:25AM EST Compass Therapeutics 10% Owner Carl Gordon Reported Purchase of 5,357,143 Shares @ Avg Price of $3.50/Share in Form 4 Filing on Monday Benzinga

Nov 2, 2021

11:11AM EDT Mid-Morning Market Update: Markets Edge Higher; Pfizer Boosts FY21 Outlook Benzinga

Oct 20, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021 Benzinga

06:06AM EDT HC Wainwright & Co. Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $11 Benzinga

Sep 20, 2021

08:35AM EDT Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. GlobeNewswire Inc

Sep 10, 2021

08:35AM EDT Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. GlobeNewswire Inc

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Share